-
Sector Analysis
Nuclear Imaging Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Nuclear Imaging Systems Market Report Overview The nuclear imaging systems market size was valued at $1.07 billion in 2023. The nuclear imaging systems market will grow at a CAGR of more than 2% from 2023 to 2033. Nuclear Imaging is a non-invasive medical technique that uses radioactive tracers (generally F-18 Fluorodeoxyglucose) to assess and diagnose bodily functions and diseases, including cancers, cardiac diseases, gastrointestinal, endocrine, and neurological diseases. Nuclear Imaging Systems Market Outlook 2023-2033 ($ Billion) Buy the Full Report...
-
Sector Analysis
Nuclear Imaging Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Nuclear Imaging Equipment Market Report Overview The nuclear imaging equipment market size was valued at $2.90 billion in 2023 and is expected to grow at a CAGR of more than 7% during 2023 and 2033. Nuclear imaging is a non-invasive medical technique that uses radioactive tracers (generally F-18 Fluorodeoxyglucose) to assess and diagnose bodily functions and diseases. The diseases include cancers, cardiac diseases, gastrointestinal, endocrine, and neurological diseases. Nuclear Imaging Equipment Market Outlook 2023-2033 ($ Billion) Buy The Full Report...
-
Product Insights
Contrast Agents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Contrast Agents Pipeline Market Report Overview The Contrast Agents pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments · Positron Emitting Tomography Contrast Agents · Magnetic Resonance Imaging (MRI) Contrast Agents · Gadolinium-based MRI Contrast Agents...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FX-5A in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FX-5A in Atherosclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.FX-5A in AtherosclerosisDrug Details:FX-5A is under development for the treatment of atherosclerosis and heart...
-
Product Insights
Nuclear Imaging Equipment Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Nuclear Imaging Equipment Pipeline Market Report Overview Nuclear Imaging Equipment makes use of radioactive substances (also called as nuclear medicine or radiopharmaceuticals) that are inserted into the body orally or intravenously. These systems capture the radiations emitted by radiopharmaceuticals to create images of the structures and activities inside the human body. These images enable physicians to look inside a human body to help determine the cause of an illness or injury and provide an accurate diagnosis. The nuclear imaging equipment...
-
Company Profile
nVent Electric Plc – Company Profile
nVent Electric Plc (nVent) designs and manufactures electrical connection and protection products. The company provides enclosures, thermal management, and electrical and fastening solutions. Its enclosures services provide solutions to protect heat in electronics, communication, control, and power equipment. nVent's thermal management provides electric thermal solutions that connect critical buildings, infrastructure, and industrial processes. The company's electrical and fastening solutions consist of fastening solutions to connect and protect electrical and mechanical systems, and civil structures. It sells its products under the...
Add to Basket -
Product Insights
Aprinoia Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Aprinoia Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Aprinoia Therapeutics Inc (Aprinoia) is a biotechnology company that provides diagnostic tools and novel therapies for the treatment of human neurological conditions. Its product pipeline includes florzolotau (18F), a PET imaging tracer; 18F-APN-1701, a PET imaging agent targeted for Alzheimer’s and Tauopathies; α-synuclein proteins for Parkinson’s disease; APNmAb005; tau modulator; degrader candidates to capture pathological tau species targeted for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FX-5A
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry FX-5A Drug Details FX-5A is under development for the treatment of atherosclerosis and heart...
-
Product Insights
Positron Emission Tomography (PET) Systems Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021
A Positron Emission Tomography (PET) scan is an imaging test that helps reveal how your tissues and organs are functioning. A PET scan uses a radioactive drug (tracer) to show this activity. GlobalData's Medical Devices sector report, “Positron Emission Tomography (PET) Systems - Medical Devices Pipeline Product Landscape, 2021" provides comprehensive information about the Positron Emission Tomography (PET) Systems pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are...
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...